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Ocular changes due to systemic alpha-interferon therapy
for hepatitis C
Purpose: To describe ocular (specially fundoscopic) changes due to
systemic alpha-interferon (IFN) therapy in patients with hepatitis C. This
is a prospective, descriptive and observational (non-interventional) study,
and its results are preliminary. Methods: Patients were selected with
indication of alpha-interferon therapy for hepatitis C. They underwent
ocular examinations before therapy and 1, 3, 6 and 12 months after starting
the therapy. HIV patients and those who had a history of previous
treatment with alpha-interferon were excluded from the study, but examined.
Results: Fifty-one patients were selected from November 1999 to June
2000. The male-to-female ratio was 1.55. The age average was 47 years. The
best corrected visual acuity ranged from 20/15 to 20/40. Most of the
symptomatic patients complained of foreign body sensation in the eyes,
which became more tolerable with time. Complaints comprised flu-like
symptoms, joint pain, depression, headache, and general weakness. Ocu-
lar findings related to alpha-interferon were: cotton wool spots (3 eyes) and
intraretinal hemorrhage (1 eye). One patient died during the study, due to
another disease not related to hepatitis, and one patient refused to be
examined. Conclusions: There are retinal vascular changes due to systemic
alpha-interferon for hepatitis C. There are no studies in our country
describing ocular changes in patients with hepatitis C on therapy with
alpha-interferon. General physicians and specially gastroenterologists
should pay special attention to this problem, and refer these patients to the
ophthalmologist in order to determine and follow any lesion that may be
related to the use of this drug.
ABSTRACT
Keywords: Hepatitis C/drug therapy; Interferon-alpha/therapeutic use; Retina diseases/
etiology
INTRODUCTION
Interferons are a group of glycoproteins that modulate the activity of
the immunological system. They can be divided into 3 groups, α, β, γ.
Interferon α acts through monocytes and lymphocytes modulating the
synthesis of immunoglobulin. Recombinant alpha-interferon (IFN) has re-
cently been approved as a therapy for chronic hepatitis C, for its antiviral
effects and to inhibit cell proliferation.
Therapy with IFNα has been associated with the presence of systemic
side effects, such as flu-like syndrome, arthralgia, platelet reduction, leukope-
nia(1), depression, delirium, thyroid disorders(2) and ocular side effects(3-5,8-11).
There are descriptions in the literature(1,4,12-24) of retinal vascular abnormalities
(retinal microvascular changes, presence of cotton-wool spots, intraretinal
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hemorrhages, retinal detachment) due to this drug. Mostly, the
ocular changes are transient and asymptomatic(12-13,16). Howe-
ver, in some special cases an aggressive intervention should be
carried out, such as retinal photocoagulation or surgery(10-11,23-26).
PURPOSE
There are no studies in our country regarding this issue.
Our purpose is to describe ocular (with special attention to
fundoscopy) changes due to IFN. This is a prospective, des-
criptive and observational (non-interventional) study, and its
results are preliminary.
METHODS
From November 1999 to June 2000, all patients with a
diagnosis of chronic hepatitis C that fulfilled the criteria for
treatment were selected. The standard therapy consisted of:
IFN 3MU three times per week plus ribavirin 1 g daily, during
12 months. Exclusion criteria were: a) HIV co-infection, b)
diabetes mellitus, hypertension or renal failure and c)
previous exposure to IFN.
Ocular examination consisted of best corrected visual
acuity measurement, refraction, anterior segment biomicros-
copy, IOP, dilated fundoscopy and fundus biomicroscopy
before and 1, 3, 6 and 12 months after starting therapy.
RESULTS
Initially, 51 patients fulfilled the criteria for IFN therapy,
but 20 of them were excluded, due to the following reasons:
HIV-positive (n=3); previous exposure to IFN (n=6); no com-
pliance with the follow-up visits (n=9); renal failure (n=1) and
one patient died during the study time, due to a disease not
related to hepatitis (cardiac arrest). These patients, although
not included in the study, have been observed until the end of
the therapy.
Follow-up was carried out for the remaining 31 patients.
The male-to-female ratio was 1.58 (61% male) and the median
age was 44.1 years (range 25-66 years). General complaints
were joint pain, psychiatric disturbances, headache, and ge-
neral weakness (Figure 1). Best corrected visual acuity ranged
from 20/15 to 20/40 and IOP levels ranged between 9 and 20
mmHg. Symptomatic patients complained of foreign body sen-
sation in the eyes mainly in the first 2 months of therapy,
becoming more tolerable with time.
Ocular findings related to IFN were development of cotton
wool spots (3 eyes) and retinal hemorrhage (1 eye). In one
patient with previous exposure to IFN, vitreous hemorrhage,
cotton wool spots, hard exudates and vascular tortuosity
although asymptomatic were observed. Other ocular findings
included hordeolum (n=1) and toxoplasmosis scarred chorio-
retinitis (n=2). Two HIV patients presented unilateral scarred
retino-choroiditis due to toxoplasmosis, one of which was
characterized as Jensen’s papillitis.
DISCUSSION
In our study, there were no cases of severe ocular complica-
tions due to the administration of systemic IFN. The only case
of retinopathy started less than 2 months after the beginning of
the therapy, and did not lead to any ocular symptom. Still, the
retinopathy did not resolve spontaneously by the time this
patient died of cardiac infarction. The other case of retinopathy
was excluded from the study, due to past personal history of
hypertension, diabetes mellitus and chronic renal insufficiency,
but was followed up. Therefore, the retinal findings in this
patient could not be associated only with IFN itself.
In the international literature, the incidence of retinopathy
associated with IFN ranges from 18 to 86%(27). This variation
can be explained by the amount of analyzed patients, the
associated risk factors, and indication of IFN administration.
Some studies report disappearance of the retinopathy even
with maintenance of the therapy(2,4,12,16), while others describe
its persistence(13,15). There are several clinical evolutions, and
most of them are benign. One single case is about a patient
that presented a disarrangement of the basic structures of the
eye and infiltration of inflammatory cells, leading to eyeball
rupture(25). This is probably the most severe case of ocular
complication by IFN.
The pathogenesis of retinopathy is not totally clear. Seve-
ral theories have been formulated to explain the mechanisms
of retinal dysfunction:
• Obstruction of axoplasmatic flow secondary to ischemia of
the retinal vasculature, causing cotton wool spots(22,28).
• The presence of cotton-wool spots and retinal hemorrha-
ges indicates that probably there is an impairment of reti-
nal blood circulation and somehow there might be retinal
ischemia(1,14,21). According to the authors, the dysfunc-
tions are similar to those found in diabetic retinopathy.
• Decreased platelet counts, increased triglyceride levels
and diabetes mellitus. Hypoalbuminemia decreases the
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Figure 1 - Ocular and general complaints of patients undergoing IFN
therapy
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plasma oncotic pressure difference between interstitial
fluids(1,15).
• Intra-arterial obstruction by leukoaggregated embolization
results from complement activation with IFN alpha causing
synergistic elevation of C5a levels, the complement com-
ponent responsible for granulocyte shape alteration and
aggregation(1,20,28). According to those studies, C5a levels
increased 5 to 10 times in patients with retinal complica-
tions on IFN therapy as compared with those without
retinal complications. IFN alpha has been shown to increa-
se leukocyte adhesion to vascular endothelium in rats(15).
The three typical fundus changes are: retinal hemorrhage,
cotton-wool spots, and nerve fiber layer defect21. Patients
with previous history of diabetes mellitus are more suscepti-
ble to the development of retinopathy(1,4,14-15). Ocular pain is
not likely to be related to retinopathy(16-17,21). Because this
retinopathy is usually mild and seldom induces visual symp-
toms, the therapy can be continued in most patients. Howe-
ver, severe retinal damage carries the risk of complete loss of
vision. Therefore, careful monitoring of retinal lesions is re-
quired in patients receiving IFN therapy, especially in those
with underlying diabetes mellitus or hypertension.
There is no classification for IFN-induced retinopathy,
like diabetic retinopathy. Therefore there is no rule for sus-
pending the use of interferon in patients who develop retino-
pathy or any other ocular side effects. The common sense for
most authors is that careful monitoring should be performed
in the presence of any ocular sign, even without symp-
toms(3,12-14,16,19-20,27,29). The ophthalmic intervention is of cru-
cial importance in order to keep satisfactory ocular function,
even if invasive procedures are necessary, such as laser
retinal photocoagulation or eye surgery(8,25).
CONCLUSION
In the present study, retinal abnormalities, although
asymptomatic were found in the eyes of patients undergoing
IFN therapy for hepatitis C. In our country, there are no stu-
dies describing the features of these microvascular abnormali-
ties or their epidemiology. Since this is a preliminary study,
further research on this issue must be carried out, probably
with a more significant amount of cases. Patients undergoing
the therapy should always be referred to the ophthalmologist
in order to determine and follow any lesion that may be related
to the use of this drug.
RESUMO
Objetivo: Avaliar alterações oculares (em especial lesões fun-
doscópicas) em pacientes com hepatite C tratados com alfa-
interferon (IFN). Métodos: Estudo prospectivo, descritivo e
observacional de pacientes com hepatite C do serviço de
Gastroenterologia da UNIFESP com indicações de uso de alfa-
interferon entre novembro de 1999 e junho de 2000. Esses
pacientes foram submetidos a exame oftalmológico completo
antes e 1, 3, 6 e 12 meses após o início do tratamento. Pacien-
tes HIV positivos, ou com exposição prévia à droga foram
excluídos. Resultados: De um total de 51 pacientes seleciona-
dos, 31 foram acompanhados. A relação masculino-feminino
foi de 1,55, e a média de idade de 47 anos. A acuidade visual
corrigida variou de 20/15 a 20/40. Vinte e dois por cento dos
pacientes queixaram-se de sensação de corpo estranho, prin-
cipalmente nos dois primeiros meses de terapia. Queixas ge-
rais foram: artralgia, cefaléia, depressão, fraqueza muscular.
Achados oculares foram: hemorragia retiniana (um olho) e
exsudatos moles (três olhos), todos assintomáticos. Em um
paciente com história pregressa de tratamento com interferon,
observou-se presença de hemorragia vítrea, exsudatos duros
e moles e tortuosidade vascular. Um paciente faleceu durante
o tratamento por infarto cardíaco. Conclusões: Existem altera-
ções oculares por uso sistêmico de alfa-interferon. Não exis-
tem estudos no nosso país descrevendo essas alterações.
Médicos clínicos gerais e gastroenterologistas devem prestar
atenção a esse tipo de problema, e encaminhar os pacientes a
um serviço de oftalmologia para acompanhamento paralelo.
Descritores: Hepatite C/quimioterapia; Alfa-interferon/uso
terapêutico; Retinopatia/etiologia.
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